[go: up one dir, main page]

WO2008033807A3 - Combinaisons synergiques d'oxydants mitochondriaux antinéoplasiques se liant au thiol et d'inhibiteurs du protéasome antinéoplasiques pour le traitement du cancer - Google Patents

Combinaisons synergiques d'oxydants mitochondriaux antinéoplasiques se liant au thiol et d'inhibiteurs du protéasome antinéoplasiques pour le traitement du cancer Download PDF

Info

Publication number
WO2008033807A3
WO2008033807A3 PCT/US2007/078119 US2007078119W WO2008033807A3 WO 2008033807 A3 WO2008033807 A3 WO 2008033807A3 US 2007078119 W US2007078119 W US 2007078119W WO 2008033807 A3 WO2008033807 A3 WO 2008033807A3
Authority
WO
WIPO (PCT)
Prior art keywords
antineoplastic
cancer
treatment
thiol
proteasome inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/078119
Other languages
English (en)
Other versions
WO2008033807A2 (fr
Inventor
Robert T Dorr
David S Alberts
Evan M Hersh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Arizona's Public Universities
Original Assignee
University of Arizona
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona, Arizona's Public Universities filed Critical University of Arizona
Publication of WO2008033807A2 publication Critical patent/WO2008033807A2/fr
Publication of WO2008033807A3 publication Critical patent/WO2008033807A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des méthodes utiles dans le traitement du cancer. Des modes de réalisation de la présente invention incluent des compositions et des méthodes faisant appel à une combinaison synergique d'un oxydant mitochondrial antinéoplasique se liant au thiol et d'un inhibiteur du protéasome antinéoplasique.
PCT/US2007/078119 2006-09-13 2007-09-11 Combinaisons synergiques d'oxydants mitochondriaux antinéoplasiques se liant au thiol et d'inhibiteurs du protéasome antinéoplasiques pour le traitement du cancer Ceased WO2008033807A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84425706P 2006-09-13 2006-09-13
US60/844,257 2006-09-13

Publications (2)

Publication Number Publication Date
WO2008033807A2 WO2008033807A2 (fr) 2008-03-20
WO2008033807A3 true WO2008033807A3 (fr) 2008-10-09

Family

ID=39184497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078119 Ceased WO2008033807A2 (fr) 2006-09-13 2007-09-11 Combinaisons synergiques d'oxydants mitochondriaux antinéoplasiques se liant au thiol et d'inhibiteurs du protéasome antinéoplasiques pour le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2008033807A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2623113T (lt) 2005-11-09 2017-07-10 Onyx Therapeutics, Inc. Junginiai, skirti fermentų slopinimui
PL2041158T3 (pl) 2006-06-19 2013-08-30 Onyx Therapeutics Inc Peptydowe epoksyketony do hamowania proteasomu
ES2684340T3 (es) 2007-10-04 2018-10-02 Onyx Therapeutics, Inc. Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos
EP2349313A4 (fr) * 2008-10-21 2012-08-29 Onyx Therapeutics Inc Thérapie de combinaison avec des peptides époxycétones
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2011060179A1 (fr) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Utilisation de peptides epoxycetones pour la suppression de la metastase
EA201290844A1 (ru) 2010-03-01 2013-03-29 Оникс Терапьютикс, Инк. Соединения для ингибирования иммунопротеасом
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
CN104974221B (zh) * 2014-04-03 2020-10-23 中国医学科学院药物研究所 二肽及三肽类蛋白酶体抑制剂及其制法和药物用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DVORAKOVA ET AL.: "Induction of mitochondrial changes in myeloma cells by imexon", BLOOD, vol. 97, 2001, pages 3544 - 3551 *
KONG ET AL.: "Mitochondrial effects with ceramide-induced cardiac apoptosis are different from those of palmitate", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 412, 2003, pages 196 - 206 *
LEYEN ET AL.: "Proteasome inhibition protects HT22 neuronal cells from oxidative glutamate toxicity", JOURNAL OF NEUROCHEMISTRY, vol. 92, 2005, pages 824 - 830 *
NEWTON ET AL.: "Functional inactivation of the oestrogen receptor by the antioestrogen, ZM 182780, sensitizes tumour cells to reactive oxygen species", JOURNAL OF ENDOCRINOLOGY, vol. 161, 1999, pages 199 - 210 *
VIRAG ET AL.: "Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death", J. OF IMMUNOLOGY, vol. 161, 1998, pages 3753 - 3759 *

Also Published As

Publication number Publication date
WO2008033807A2 (fr) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008033807A3 (fr) Combinaisons synergiques d'oxydants mitochondriaux antinéoplasiques se liant au thiol et d'inhibiteurs du protéasome antinéoplasiques pour le traitement du cancer
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
WO2008060622A3 (fr) Méthodes et compositions améliorées pour la cicatrisation des plaies
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
ZA200708575B (en) Methods and compositions for treating or preventing cancer
WO2010066639A3 (fr) Compositions d'éclaircissement de la peau avec des inhibiteurs d'acétylcholinestérase
MX2007012732A (es) Derivados de azol en forma de inhibidores de lipasas y fosfolipasas.
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3
WO2012073047A3 (fr) Compositions et procédés
EP2037941B8 (fr) Compositions de cobalamine destinés au traitement ou à la prévention de mucosite
TN2012000205A1 (en) Method and compositions for treating solid tumors and other malignancies
WO2007081751A9 (fr) Compositions et procedes destines au traitement du cancer
WO2007059154A3 (fr) Traitement de cancers a resistance acquise a des inhibiteurs de kit
IL187728A0 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
IL187730A0 (en) Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors
IL187729A0 (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
WO2009108755A3 (fr) Compositions pharmaceutiques pour le traitement du cancer
GB0625100D0 (en) Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
WO2005079849A3 (fr) Composes pour la traitement ameliore du cancer
EP1733743A4 (fr) Agents de prevention/remedes contre le cancer
WO2006127978A3 (fr) Compositions et methodes de traitement du cancer
WO2008063778A3 (fr) Combinaisons synergiques d'oxydants mitochondriaux antinéoplasiques se liant au thiol et de corticostéroïdes antinéoplasiques pour le traitement du cancer
WO2006074443A3 (fr) Compositions d'inhibiteur des pde5 et procedes pour l'immunotherapie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842222

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07842222

Country of ref document: EP

Kind code of ref document: A2